Trade Cardiff Oncology, Inc. - CRDF CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0314 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024818% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002596% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.5143 |
| Open | 2.5043 |
| 1-Year Change | 55.07% |
| Day's Range | 2.5043 - 2.6843 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 19, 2024 | 2.5143 | 0.0000 | 0.00% | 2.5143 | 2.6943 | 2.4343 |
| Sep 18, 2024 | 2.4543 | -0.1500 | -5.76% | 2.6043 | 2.6443 | 2.4143 |
| Sep 17, 2024 | 2.5243 | -0.0200 | -0.79% | 2.5443 | 2.6043 | 2.4343 |
| Sep 16, 2024 | 2.5543 | -0.1400 | -5.20% | 2.6943 | 2.8043 | 2.4543 |
| Sep 13, 2024 | 2.6843 | 0.2000 | 8.05% | 2.4843 | 2.7443 | 2.4843 |
| Sep 12, 2024 | 2.5443 | 0.2600 | 11.38% | 2.2843 | 2.6643 | 2.2743 |
| Sep 11, 2024 | 2.3043 | 0.1300 | 5.98% | 2.1743 | 2.3043 | 2.1643 |
| Sep 10, 2024 | 2.2816 | 0.1100 | 5.07% | 2.1716 | 2.3116 | 2.1716 |
| Sep 9, 2024 | 2.2916 | 0.2200 | 10.62% | 2.0716 | 2.3116 | 2.0716 |
| Sep 6, 2024 | 2.0916 | -0.1300 | -5.85% | 2.2216 | 2.2416 | 2.0816 |
| Sep 5, 2024 | 2.1916 | 0.0500 | 2.33% | 2.1416 | 2.2216 | 2.1016 |
| Sep 4, 2024 | 2.1716 | 0.0000 | 0.00% | 2.1716 | 2.2316 | 2.1316 |
| Sep 3, 2024 | 2.1816 | -0.0600 | -2.68% | 2.2416 | 2.2916 | 2.1416 |
| Aug 30, 2024 | 2.2816 | 0.0200 | 0.88% | 2.2616 | 2.3016 | 2.2216 |
| Aug 29, 2024 | 2.2716 | 0.0100 | 0.44% | 2.2616 | 2.3516 | 2.2216 |
| Aug 28, 2024 | 2.2816 | -0.0200 | -0.87% | 2.3016 | 2.3116 | 2.2316 |
| Aug 27, 2024 | 2.3216 | -0.0400 | -1.69% | 2.3616 | 2.4016 | 2.2716 |
| Aug 26, 2024 | 2.3816 | -0.0300 | -1.24% | 2.4116 | 2.4316 | 2.3516 |
| Aug 23, 2024 | 2.3716 | 0.1100 | 4.86% | 2.2616 | 2.4516 | 2.2616 |
| Aug 22, 2024 | 2.2816 | -0.0200 | -0.87% | 2.3016 | 2.3316 | 2.2616 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cardiff Oncology, Inc. Company profile
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company''s onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.| Industry: | Biotechnology & Medical Research (NEC) |
11055 Flintkote Ave
SAN DIEGO
CALIFORNIA 92121
US
News
RBA Preview: Rates to remain unchanged with inflation-fighting still the focus
RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.
12:27, 20 September 2024
BoE Preview: no change expected but forward guidance will be key
The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.
14:53, 19 September 2024
FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion
Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.
11:30, 19 September 2024
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com